首页> 外文OA文献 >The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors
【2h】

The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors

机译:腺苷脱氨酶的阻断可通过募集腺苷A2A和A3受体改善慢性实验性结肠炎

摘要

Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase blockade. Adenosine deaminase expression was determined by Western blot. The effects of 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine (APP; a novel adenosine deaminase inhibitor), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; a reference adenosine deaminase inhibitor), dexamethasone, and selective adenosine receptor antagonists were tested in rats with 2,4-dinitrobenzenesulfonic acid-induced colitis. Systemic (food intake, body and spleen weight) and colonic [macroscopic/microscopic damage, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and malondialdehyde (MDA)] inflammatory parameters were assessed. Test drugs were administered intraperitoneally for 6 days, starting at day 5 from colitis induction. Adenosine deaminase was detected in normal colon, and its expression was increased in inflamed tissues. Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA. APP or EHNA, but not dexamethasone, improved food intake and body weight. APP, EHNA, and dexamethasone counteracted the increments of spleen weight, ameliorated macroscopic and microscopic indexes of inflammation, and reduced TNF-α, IL-6, and MDA levels. The beneficial effects of APP and EHNA on inflammatory parameters were prevented by the pharmacological blockade of A2A or A3 receptors, but not A1 or A2B. The present results show that: 1) bowel inflammation is associated with an enhanced adenosine deaminase expression; and 2) the anti-inflammatory actions of adenosine deaminase inhibitors against chronic established colitis depend on the sparing of endogenous adenosine, leading to enhanced A2A and A 3 receptor activation.
机译:腺苷调节免疫/炎症反应。这项研究调查了炎症结肠中腺苷脱氨酶的表达,腺苷脱氨酶抑制剂对已建立的结肠炎的影响以及腺苷脱氨酶阻断后内源性腺苷对腺苷受体的募集作用。腺苷脱氨酶表达通过蛋白质印迹法确定。 4-氨基-2-(2-羟基-1-癸基)吡唑[3,4-d]嘧啶(APP;新型腺苷脱氨酶抑制剂),赤型-9-(2-羟基-3-壬基)的作用在患有2,4-二硝基苯磺酸诱导的结肠炎的大鼠中测试了腺嘌呤(EHNA;参考腺苷脱氨酶抑制剂),地塞米松和选择性腺苷受体拮抗剂。评估全身性(食物摄入量,体重和脾脏重量)和结肠[宏观/微观损伤,肿瘤坏死因子-α(TNF-α),白介素-6(IL-6)和丙二醛(MDA)]的炎症参数。从结肠炎诱发的第5天开始,腹膜内给予测试药物6天。在正常结肠中检测到腺苷脱氨酶,并且在发炎的组织中其表达增加。结肠炎与食物摄入量和体重减少,脾脏重量增加以及结肠TNF-α,IL-6和MDA水平升高有关。 APP或EHNA可以改善食物摄入量和体重,但不能增加地塞米松。 APP,EHNA和地塞米松可抵消脾脏重量的增加,炎症的宏观和微观指标得到改善,并降低TNF-α,IL-6和MDA水平。通过A2A或A3受体的药理学阻断作用阻止了APP和EHNA对炎症参数的有益作用,但没有阻止A1或A2B的作用。目前的结果表明:1)肠道炎症与腺苷脱氨酶表达增强有关; 2)腺苷脱氨酶抑制剂对慢性结肠炎的抗炎作用取决于内源性腺苷的保留,从而导致增强的A2A和A 3受体活化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号